Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

(2011) Philip Robson   Expert Opinion On Drug Safety

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study

(2011) Rafael Arroyo et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Pharmacotherapy for Cannabis Dependence

(2009) Ryan Vandrey et al.   CNS DRUGS